Clinical Trial

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by…

12 months ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical…

12 months ago

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocolQ2 2023 consolidated revenue were affected by specialty…

12 months ago

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Accomplished Industry Veteran Brings Deep Strategic and Operational ExpertiseCAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq:…

12 months ago

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a…

12 months ago

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled…

12 months ago

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to…

12 months ago

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern TimeNEW YORK, July 12,…

12 months ago

Psyence Group Corporate Update

Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010…

12 months ago

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’sROME, July 12, 2023 (GLOBE…

12 months ago